Ajanta Pharma has received USFDA approval for Clonidine Hydrochloride Extended Release Tablets. It will launch the tablets in the US market, via its wholly owned subsidiary Ajanta Pharma USA Inc.

It is a generic bioequivalent of Kapvay Tablets and the company will launch it in 0.1 mg dosage. Ajanta Pharma has launched 16 products in the US market till now.

Further, it has 39 Abbreviated New Drug Applications (ANDAs), out of which it has 22 final ANDA approvals, 2 tentative approvals and 15 ANDAs  are under review with USFDA.

Read EquityPandit’s Technical Analysis on Nifty Pharma